Exscientia PLC
NASDAQ:EXAI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
Herantis Pharma Oyj
OMXH:HRTIS
|
FI |
Exscientia PLC
Intangible Assets
Exscientia PLC
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Exscientia PLC
NASDAQ:EXAI
|
Intangible Assets
£28.5m
|
CAGR 3-Years
422%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Intangible Assets
£52m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-3%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Intangible Assets
£25.2m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
222%
|
CAGR 10-Years
31%
|
|
Exscientia PLC
Glance View
Exscientia Plc operates as an AI-driven pharmatech company which is engaged in designing and developing patient-based drugs. The company is headquartered in Oxford, Oxfordshire and currently employs 208 full-time employees. The company went IPO on 2021-10-01. The firm's focus is on the discovery, design and development of small molecule drug candidates. The firm has built a complete end-to-end solution of artificial intelligence (AI), and experimental technologies for target identification, drug candidate design, translational models and patient selection. Its AI process is comprised of the four elements: Precision Target, Precision Design, Precision Experiment and Precision Medicine. Its AI-design includes a range of deep learning and machine learning algorithms, generative methods, active learning and natural language processing. These methods are used to guide target selection, to design the precise molecular architecture of potential drug molecules and to analyze patient tissues to prioritize the molecules. The firm's lead drug candidate, EXS21546, is in early stage of development.
See Also
What is Exscientia PLC's Intangible Assets?
Intangible Assets
28.5m
GBP
Based on the financial report for Dec 31, 2023, Exscientia PLC's Intangible Assets amounts to 28.5m GBP.
What is Exscientia PLC's Intangible Assets growth rate?
Intangible Assets CAGR 3Y
422%
Over the last year, the Intangible Assets growth was -30%. The average annual Intangible Assets growth rates for Exscientia PLC have been 422% over the past three years .
